Laura Blue

Left ventricular assist device as destination therapy in doxorubicin-induced cardiomyopathy.

Graft vascular disease after cardiac transplantation and its relationship to mean acute rejection score.

Outcomes with an alternate list strategy for heart transplantation.

Implantable left ventricular assist devices: new hope for patients with end-stage heart failure.

Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients.

Left ventricular assist device destination therapy versus extended criteria cardiac transplant.

Impact of tricuspid valve regurgitation in patients treated with implantable left ventricular assist devices.

Presentation and management of left ventricular assist device inflow cannula malposition.

Clinical impact of concomitant tricuspid valve procedures during left ventricular assist device implantation.

Dysphagia in the setting of left ventricular assist device hemolysis.

Outcomes after implantable left ventricular assist device replacement procedures.

Thrombolytic therapy for thrombosis of continuous flow ventricular assist devices.

Improved early survival with a nonsternotomy approach for continuous-flow left ventricular assist device replacement.

Comparison of 2-Year Outcomes of Extended Criteria Cardiac Transplantation Versus Destination Left Ventricular Assist Device Therapy Using Continuous Flow.

Reduce Driveline Trauma Through Stabilization and Exit Site Management: 30 Days Feasibility Results from the Multicenter RESIST Study.

Effectiveness of an Intervention Supporting Shared Decision Making for Destination Therapy Left Ventricular Assist Device: The DECIDE-LVAD Randomized Clinical Trial.